60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
Want to see SXTP full AI Analyst Report?
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▲(200.00% Upside)
Action:Reiterated
Date:06/04/26
The score is held down primarily by large ongoing losses and significant, worsening cash burn versus a very small revenue base, despite low leverage and positive equity. Technicals add pressure with a clear downtrend below key moving averages and negative MACD, while valuation is constrained by negative earnings and no dividend support. Corporate updates are directionally positive but remain conditional and include potential dilution considerations.
Positive Factors
Focused infectious-disease franchise
A concentrated therapeutic focus on malaria and infectious diseases delivers durable product and regulatory expertise. Marketed malaria therapeutics plus pipeline programs create repeatable commercialization and clinical development capabilities that support long-term addressable markets and partnership appeal.
Negative Factors
Accelerating cash burn
Sustained, worsening negative cash flow is a structural constraint that depletes resources and forces external financing. Persistent burn limits R&D and commercialization flexibility, raises survival dependence on trial outcomes, and increases execution risk absent durable revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused infectious-disease franchise
A concentrated therapeutic focus on malaria and infectious diseases delivers durable product and regulatory expertise. Marketed malaria therapeutics plus pipeline programs create repeatable commercialization and clinical development capabilities that support long-term addressable markets and partnership appeal.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.78M
Dividend YieldN/A
Average Volume (3M)199.18K
Price to Earnings (P/E)―
Beta (1Y)2.40
Revenue Growth66.12%
EPS Growth91.75%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.53
Enterprise Value/Revenue-1.98
Enterprise Value/Gross Profit-9.45
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$3.70Price Target Upside640.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevent...
How the Company Makes Money
null...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | |||||
| Total Assets | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | |||||
| Free Cash Flow | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
0.50
Price Trends
1.62
Negative
2.34
Negative
3.53
Negative
Market Momentum
-0.06
Negative
42.11
Neutral
44.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.62, and below the 200-day MA of 3.53, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of 44.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.78M | -0.32 | -212.63% | ― | 66.12% | 91.75% | |
| ― | $2.68M | -0.26 | -168.95% | ― | ― | 84.00% | |
41 Neutral | $38.30M | -0.85 | -1335.64% | ― | ― | 66.47% | |
| ― | $1.18M | -0.07 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
1.42
-10.18
-87.76%
OGEN
Oragenics
0.59
-3.74
-86.28%
KALA
KALA BIO
2.06
-203.44
-99.00%
KTTA
Pasithea Therapeutics Corp
0.59
-0.32
-35.00%
SPRC
SciSparc Ltd.
11.44
-49.99
-81.38%
ONCO
Onconetix
1.03
-337.69
-99.70%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Business Operations and Strategy
60 Degrees details tafenoquine priority review voucher strategy
Positive
Jun 3, 2026
60 Degrees Pharmaceuticals disclosed that it plans to apply for a Commissioner’s National Priority Review Voucher if interim or final results from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe b...
Regulatory Filings and ComplianceStock Split
60 Degrees Updates Affiliate Share Ownership Disclosure Error
Neutral
Mar 20, 2026
On March 20, 2026, 60 Degrees Pharmaceuticals, Inc. reported that it had miscalculated the number of shares of common stock beneficially owned by a company affiliate in a prospectus supplement dated March 13, 2026. The affiliate’s holdings w...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
Neutral
Mar 13, 2026
On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion covering the shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright Co., LLC, originally established under a Sep...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Opinion for ATM Program
Positive
Mar 12, 2026
On March 12, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel covering shares of common stock issued and sold under its at-the-market equity offering program established under a September 5, 2025 sales agreement wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.